ClinicalTrials.gg
RecruitingNCT06279741EVENEWUpdated Sep 19, 2024

Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants

A Phase 1/2 interventional study of Endotracheopulmonary Instillation, Suspension in Bronchopulmonary Dysplasia, sponsored by EXO Biologics S.A.. Recruiting at 8 sites in 2 countries. Open to participants aged Up to 10 Days. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by EXO Biologics S.A. · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
Up to 10 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Bronchopulmonary Dysplasia with a site in Italy — 6 open to participants now, 8 under way, 1 of them phase 3. Bronchopulmonary Dysplasia · Italy.

Planned enrollment
6th of 12
265 · median 193
Started
2023
with 2 others
Phase 1/2
Only one
of the 16
Registered
13th of 16
by date
Lead sponsor
1 of 16
EXO Biologics S.A.

Among the 16 studies in Bronchopulmonary Dysplasia with a site in Italy, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1/2, and was the 13th registered.

Bronchopulmonary Dysplasia

363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.

Browse Bronchopulmonary Dysplasia studies →

Open to participants now

6 of the 16 studies in Bronchopulmonary Dysplasia with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.

This study: Up to 10 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Bronchopulmonary Dysplasia with a site in Italy, or all of them as a file.
02

Study summary

The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in extremely premature neonates. The study population includes babies born between 23 and 28 (27 + 6 days) weeks of gestational age and body weight between 500g and 1,500 g. Thirty-six subjects will receive one or three administrations of the three doses of EXOB-001 via the endotracheal route in phase 1. In phase 2, two dosages based on the results of phase 1 will be selected and a total of 203 subjects will be randomised to receive either EXOB-001 or placebo (saline solution).

Infants will be followed up to 2 years of corrected age (end of study).

Read the detailed description

Bronchopulmonary Dysplasia (BPD) is a chronic severe multifactorial respiratory disease that affects extremely premature infants and is the most common and severe consequence of preterm birth. BPD is associated with disrupted alveolarization and microvascular development, resulting in abnormal gas exchange and lung mechanics. BPD has a multifactorial aetiology, with pre-, peri-, and postnatal mechanisms causing inflammation and injury and resulting in the disruption of the lung's development with the insurgence of an aberrant repair mechanism.

EXOB-001 consists of a population of EVs smaller than 0.22 μm in diameter, containing proteins and nucleic acids, enclosed in a double layer of phospholipids with integral and surface-bound proteins as the main components. EVs exert anti-inflammatory and immunomodulatory activity by reducing the release of proinflammatory cytokines and reducing the recruitment of immune cells in the lung. Current evidence shows that EVs can modulate macrophage phenotype, and this is relevant for BPD, because of the role macrophages have in its pathogenesis.

Two hundred sixty-five (265), 40 in phase 1 (to reach 36 evaluable subjects) + 225 in phase 2 (to reach 203 evaluable subjects), extremely preterm infants at risk of developing BPD with 23 weeks up to 28 (27 weeks+6 days) weeks of gestational age and birth weight between 500g and 1,500g and being endotracheally intubated between postnatal day 3 and day 10 receiving mechanical ventilation with FiO2 > 25%.

Phase 1 will start with cohorts with a single administration starting with a low dose up to a high dose and thereafter start the escalation of cohorts with 3 administrations starting with a low dose up to a high dose. In the case of 3 endotracheal administrations, there will be a window of 24 hours between the administrations (the maximal duration of the treatment with EXOB-001 will be 48 hours).

Phase 2 includes 2 groups with selected dosage levels and regimen of EXOB-001 based on phase 1 interim results. Subjects will be randomised (2:2:1) to receive either EXOB-001 or placebo (saline solution).

03

Conditions studied

  • Bronchopulmonary Dysplasia

Keywords

  • EXOB-001
  • Extracellular vesicles
  • Bronchopulmonary dysplasia
  • Extremely premature neonates
  • Lung inflammation
04

Who can participate

Ages eligible
Up to 10 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • From birth up to 10 days chronological age.
  • From 23 weeks up to 28 weeks (27 week+6 days) gestational age at birth.
  • Birth weight ≥ 500g but ≤1500g.
  • Endotracheally intubated and receiving mechanical ventilation with FiO2 > 25% anytime between 3 and 10 days postnatally or needing re-intubation due to respiratory complications, - Not expected to be extubated within the next 24/48 hours after enrolment.
  • Written from parents/legally designated representative.

Exclusion criteria

Exclusion Criteria:

  • Surfactant administration less than 24 hours prior to (first) IMP administration.
  • Has a congenital heart defect, except for patent ductus arteriosus (PDA), atrial septal defect or a small/moderate, restrictive ventricular septal defect.
  • Has a serious malformation of the lung, such as pulmonary hypoplasia/aplasia, congenital diaphragmatic hernia, or any other congenital lung anomaly.
  • Being treated with inhaled nitric oxide.
  • Has a known chromosomal abnormality (e.g., Trisomy 18, Trisomy 13, or Trisomy 21) or a severe congenital malformation (e.g., hydrocephalus and encephalocele, trachea-oesophageal fistula, abdominal wall defects, and major renal anomalies).
  • Has had a known severe congenital infectious disease (i.e., herpes, toxoplasmosis rubella, syphilis, , cytomegalovirus, etc.).
  • Active systemic infection, severe sepsis, or septic shock at Screening up to baseline (phase I) or randomization (phase II).
  • Underwent a surgical procedure (requiring admission to an operating room) within 72 hours before baseline (phase I)/randomization (phase II) or who is anticipated to have a surgical procedure (requiring admission to an operating room) within 72 hours before or following baseline (phase I)/randomization (phase II).
  • Has had a Grade 3 or 4 intraventricular haemorrhage (IVH).
  • Has active pulmonary haemorrhage.
  • Has periventricular leukomalacia (PVL).
  • The subject is currently participating in any other interventional clinical study.
  • The subject is, in the opinion of the Investigator, so ill that death is inevitable, or is considered inappropriate for the study such as an infant that received thoracic compressions and/or adrenaline administration during stabilization in the delivery room and for any reason(s) other than those listed above.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
265 participants (estimated)

Study arms

  • Experimental
    EXOB-001 (Phase 1)

    EXOB-001 will be administered via the endotracheal route in an already intubated newborn. EXOB-001 will be administered in three dose levels (low dose, medium dose and high dose) with one or three administrations.

    Biological: Endotracheopulmonary Instillation, Suspension

  • Experimental
    Active group 1 EXOB-001 (Phase 2)

    In phase 2, active group 1 consists of administering the first (out of two) of the safest selected dose/regimen of EXOB-001 based on phase 1 interim results.

    Biological: Endotracheopulmonary Instillation, Suspension

  • Experimental
    Active group 2 EXOB-001 (Phase 2)

    In phase 2, active group 2 consists of administering the second (out of two) of the safest selected dose/regimen of EXOB-001 based on phase 1 interim results.

    Biological: Endotracheopulmonary Instillation, Suspension

  • Placebo comparator
    Placebo (Phase 2)

    In phase 2, the saline solution for infusion is used as a placebo.

    Biological: Endotracheopulmonary Instillation, Suspension

Interventions

  • BiologicalEndotracheopulmonary Instillation, Suspension

    The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube. The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant.

    Also known as: Endotracheopulmonary instillation

06

What researchers measure

Primary outcomes

  1. Number of subjects with treatment-emergent adverse events (phase 1)

    The proportion of subjects exhibiting acute and short-term safety of the intratracheal administration of EXOB-001 (single dose or multiple doses at different dose levels).

    Time frame: From EXOB-001 administration up to 36 weeks post-menstrual age (PMA)

  2. Number of subjects with BPD grade II-III incidence rate per groups (phase 2).

    BPD grade II-III incidence rate per group assessed at 36 weeks PMA. The severity of BPD is assessed according to the modified NICHD severity grading (Grade I to IIIA) definition.

    Time frame: 36 weeks PMA

Secondary outcomes

  1. Assessment of medium-term safety of EXOB-001 (phase 1/2)

    The proportion of subjects experiencing treatment-emergent adverse events (TEAE) from EXOB-001 administration up to hospital discharge

    Time frame: From EXOB-001 administration to hospital discharge (between 36 and 40 weeks PMA)

  2. Number of subjects with dose-limiting toxicity (DLT) (phase 1)

    DLT is measured as: * cardiorespiratory decompensation; * decrease in SpO2/FiO2 ratio; * stable increase in required mean airway pressure \>3 cm H2O; * death, * anaphylactic reaction. * any serious adverse reaction (SAR) considered as at least possibly related to EXOB-001 administration.

    Time frame: 6 hours and 24 hours after EXOB-001 administration

  3. Number of subjects needing for oxygen and ventilation for BPD incidence (phase 1/2)

    The number of subjects needing oxygen and ventilation support.

    Time frame: 28 days chronological age, 36 weeks PMA, 40 weeks PMA

  4. Assessment of immune markers (phase 2)

    To test immune markers in the tracheal aspirate fluid.

    Time frame: Baseline (before EXOB-001 administration), baseline + 24 hours before EXOB-001 administration, baseline + 72 hours if the the subject is still intubated

  5. Assessment of BPD incidence and severity (phase 1/2)

    The number of cases and severity of BPD were measured according to different definitions (modified NICHD severity grading (Grade I to IIIA), Jobe and Bancalari 2001, and Isayama 2017).

    Time frame: 28 days of chronological age, 36 weeks PMA and 40 weeks PMA

  6. Safety evaluation (phase 1/2)

    All adverse events (AEs) and serious adverse events (SAEs) (including case fatalities), both related and non-related.

    Time frame: From enrolment to 2 years of corrected age (end of study)

  7. Assessment of lung ultrasound score (phase 1/2)

    The lung ultrasound score (LUS) aims to assess lung development in all groups by lung ultrasound at different time points. Each lung is divided into 3 areas (upper anterior, lower anterior, lateral), and each area will be evaluated by assigning a value ranging from 0 to 3 to each zone, with a consequent overall value ranging between 0 and 18 in all infants scanned on the anterior and later thorax, and also another score (called extended lung ultrasound score or eLUS) in those infants scanned posteriorly ranging between 0 and 30. The lung ultrasound scores were assigned as follows: * 0, indicates an A-pattern (defined by the presence of the only A-lines); * 1, indicates a B-pattern (defined as the presence of ≥3 well-spaced B-lines); * 2, indicates severe B pattern (defined as the presence of crowded and coalescent B lines with or without consolidations limited to the subpleural space); * 3, indicates extended consolidations.

    Time frame: From baseline to 2 years of corrected age (end of study)

  8. Number of subjects with complications of prematurity (phase 1/2)

    To assess all known complications of prematurity, concomitant treatments/procedures/therapies in all groups.

    Time frame: From baseline to 2 years of corrected age (end of study)

  9. Assessment of the respiratory morbidity (phase 1/2)

    To evaluate the respiratory morbidity by the Liverpool Respiratory Symptom Questionnaire in all groups at different time points. Parents are asked to consider respiratory symptoms over the last 3 months, with questions being scored on a five-point Likert scale from ''not at all'' (score 0) to ''every day'' (score 4). A score for each domain and the complete questionnaire is calculated.

    Time frame: From hospital discharge to 2 years of corrected age (end of study)

  10. Assessment of neurodevelopment (phase 1/2)

    To evaluate the neurodevelopmental condition by the ASQ3 questionnaire in all groups with age-specific questionnaires at different time points. The neurodevelopment will be assessed by five domains: communication, gross motor, fine motor, problem-solving, and personal-social. Parents will fill out each item and indicate whether the baby is doing the activity regularly (10 points), sometimes (5 points), or not yet (0 points). The total score of each developmental area is compared to the area cut-offs.

    Time frame: From hospital discharge to 2 years of corrected age (end of study)

07

Study locations

2 of 8 sites recruiting
  • Cliniques Universitaires Saint-Luc (UCLouvain)
    Brussels, 1200, Belgium
    Not yet recruiting
  • ISPPC CHU Charleroi
    Charleroi, 6000, Belgium
    Not yet recruiting
  • Clinique CHC Montlégia
    Liège, 4000, Belgium
    Not yet recruiting
    • Pierre Maton, M.D. · Contactpierre.maton@chc.be · +32 4 355 56 17
    • Pierre Maton, M.D. · Principal investigator
  • AOU Careggi
    Florence, Italy
    Active, not recruiting

    Not enrolling at this site.

  • IRCCS Instituto Giannina Gaslini
    Genova, Italy
    Recruiting
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Italy
    Active, not recruiting

    Not enrolling at this site.

  • AOU Policlinico di Modena
    Modena, Italy
    Not yet recruiting
  • Unità di Fase I della UOC Terapia Intensiva e Patologia Neonatale, Assistenza Neonatale (TINI) dell'Azienda Ospedale Università di Padova
    Padua, 35128, Italy
    Recruiting
    • Eugenio Baraldi, Prof · Contacteugenio.baraldi@unipd.it · +39 049 8213578
    • Eugenio Baraldi, Prof · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Jan 2027, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 28, 2024
StartActual
Dec 28, 2023
Primary completionEst.
Jan 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06279741
Lead sponsor
EXO Biologics S.A.
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Dec 28, 2023
Primary completion
Jan 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 19, 2024

Study contacts

Beatrice De Vos, M.D., Ph.D.
Contact
b.devos@exobio.be
+32 478 88 26 57
Lorine Preud'homme, M.Sc.
Contact
l.preudhomme@exobio.be
+32 468 07 40 71
Beatrice De Vos, M.D., Ph.D.
study chair · EXO Biologics SA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion